MX2009006675A - Inhibidores de cinasa mpk/erk. - Google Patents

Inhibidores de cinasa mpk/erk.

Info

Publication number
MX2009006675A
MX2009006675A MX2009006675A MX2009006675A MX2009006675A MX 2009006675 A MX2009006675 A MX 2009006675A MX 2009006675 A MX2009006675 A MX 2009006675A MX 2009006675 A MX2009006675 A MX 2009006675A MX 2009006675 A MX2009006675 A MX 2009006675A
Authority
MX
Mexico
Prior art keywords
mapk
kinase inhibitors
erk kinase
compounds
methods
Prior art date
Application number
MX2009006675A
Other languages
English (en)
Inventor
Michael B Wallace
Stephen W Kaldor
Xianchang Gong
Nicholas Scorah
Qinq Dong
Toufike Kanouni
Feng Zhou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2009006675A publication Critical patent/MX2009006675A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan compuestos de la fórmula siguiente para uso con MEK(1); en donde las variables son como se definen en la presente. También se proporcionan composiciones farmacéuticas, kits y artículos de manufactura que comprenden tales compuestos; métodos e intermediarios útiles para la elaboración de los compuestos; y métodos de uso de los compuestos. (Ver fórmula I).
MX2009006675A 2006-12-20 2007-12-18 Inhibidores de cinasa mpk/erk. MX2009006675A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87091306P 2006-12-20 2006-12-20
PCT/US2007/087913 WO2008079814A2 (en) 2006-12-20 2007-12-18 Mapk/erk kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009006675A true MX2009006675A (es) 2009-08-12

Family

ID=39462025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006675A MX2009006675A (es) 2006-12-20 2007-12-18 Inhibidores de cinasa mpk/erk.

Country Status (35)

Country Link
US (4) US8293901B2 (es)
EP (1) EP2125810B1 (es)
JP (1) JP5513127B2 (es)
KR (1) KR101488467B1 (es)
CN (1) CN101679411B (es)
AR (1) AR064640A1 (es)
AU (1) AU2007337003B2 (es)
BR (1) BRPI0720525B8 (es)
CA (1) CA2673647C (es)
CL (1) CL2007003742A1 (es)
CO (1) CO6230984A2 (es)
CR (1) CR10937A (es)
DK (1) DK2125810T3 (es)
EA (1) EA016312B1 (es)
EC (1) ECSP099529A (es)
ES (1) ES2430966T3 (es)
GE (1) GEP20125511B (es)
HR (1) HRP20130684T1 (es)
IL (1) IL199362A (es)
JO (1) JO2985B1 (es)
MA (1) MA31151B1 (es)
MX (1) MX2009006675A (es)
MY (1) MY157871A (es)
NO (1) NO342270B1 (es)
NZ (1) NZ578310A (es)
PE (1) PE20090071A1 (es)
PL (1) PL2125810T3 (es)
PT (1) PT2125810E (es)
RS (1) RS52887B (es)
SI (1) SI2125810T1 (es)
TN (1) TN2009000249A1 (es)
TW (1) TWI396538B (es)
UA (1) UA98479C2 (es)
WO (1) WO2008079814A2 (es)
ZA (1) ZA200904682B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
KR20090071666A (ko) 2006-10-23 2009-07-01 다케다 야쿠힌 고교 가부시키가이샤 Ｍａｐｋ／ｅｒｋ 키나아제 억제제
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US8022057B2 (en) * 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CN102216274A (zh) * 2008-11-18 2011-10-12 武田药品工业株式会社 (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
AR090220A1 (es) 2012-03-01 2014-10-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
CA2868954A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
US9868737B2 (en) * 2014-06-17 2018-01-16 Cisen Pharmaceutical Co., Ltd. Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
KR102580179B1 (ko) 2017-06-23 2023-09-18 씨스톤 파마슈티컬즈 Mek억제제로서의 쿠마린 고리계 화합물 및 이의 용도
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
US20220144819A1 (en) 2018-11-20 2022-05-12 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
KR20020002370A (ko) 1999-01-13 2002-01-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 벤조헤테로사이클 및 ｍｅｋ 억제제로서의 그의 용도
WO2001055147A1 (en) 2000-01-25 2001-08-02 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
YU2503A (sh) 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
IL155367A0 (en) 2000-10-23 2003-12-23 Smithkline Beecham Corp NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
CN101486682B (zh) 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
CA2524525C (en) 2003-05-23 2012-01-03 Zentaris Gmbh Novel pyridopyrazines and use thereof as kinase modulators
AU2003277715A1 (en) 2003-07-03 2005-01-21 Sunghag Koo Ferment ginseng oil
DE602004023207D1 (de) 2003-07-24 2009-10-29 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
MXPA06001098A (es) 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
SI1682138T1 (sl) 2003-11-19 2011-04-29 Array Biopharma Inc HETEROCIKLIÄŚNI INHIBITORJI MEK-a
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MXPA06014478A (es) 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
WO2006058752A1 (en) 2004-12-01 2006-06-08 Laboratoires Serono S.A. [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
KR20090071666A (ko) * 2006-10-23 2009-07-01 다케다 야쿠힌 고교 가부시키가이샤 Ｍａｐｋ／ｅｒｋ 키나아제 억제제
JP2010509265A (ja) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US8022057B2 (en) 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CN102216274A (zh) 2008-11-18 2011-10-12 武田药品工业株式会社 (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法

Also Published As

Publication number Publication date
US20080255160A1 (en) 2008-10-16
TW200835496A (en) 2008-09-01
BRPI0720525B8 (pt) 2021-05-25
EP2125810B1 (en) 2013-04-24
NO20092692L (no) 2009-09-16
AU2007337003B2 (en) 2013-05-02
CA2673647A1 (en) 2008-07-03
ES2430966T3 (es) 2013-11-22
IL199362A (en) 2013-07-31
UA98479C2 (en) 2012-05-25
TWI396538B (zh) 2013-05-21
SI2125810T1 (sl) 2013-09-30
US20100130518A1 (en) 2010-05-27
CR10937A (es) 2009-11-20
RS52887B (en) 2014-02-28
JO2985B1 (ar) 2016-09-05
HRP20130684T1 (en) 2013-10-11
EA016312B1 (ru) 2012-04-30
AU2007337003A2 (en) 2009-07-30
DK2125810T3 (da) 2013-07-29
NZ578310A (en) 2012-01-12
JP5513127B2 (ja) 2014-06-04
KR20090091353A (ko) 2009-08-27
PT2125810E (pt) 2013-07-29
ZA200904682B (en) 2010-09-29
US20120202999A1 (en) 2012-08-09
EP2125810A2 (en) 2009-12-02
KR101488467B1 (ko) 2015-01-30
US20110065733A1 (en) 2011-03-17
AU2007337003A1 (en) 2008-07-03
CA2673647C (en) 2016-02-09
WO2008079814A3 (en) 2008-09-04
US8470837B2 (en) 2013-06-25
CN101679411B (zh) 2013-04-17
EA200970605A1 (ru) 2009-12-30
WO2008079814A2 (en) 2008-07-03
TN2009000249A1 (en) 2010-10-18
MY157871A (en) 2016-07-29
US8030317B2 (en) 2011-10-04
JP2010514680A (ja) 2010-05-06
NO342270B1 (no) 2018-04-30
BRPI0720525A2 (pt) 2014-01-07
PE20090071A1 (es) 2009-04-04
US8293901B2 (en) 2012-10-23
AR064640A1 (es) 2009-04-15
GEP20125511B (en) 2012-05-10
CL2007003742A1 (es) 2008-06-13
CN101679411A (zh) 2010-03-24
PL2125810T3 (pl) 2013-09-30
BRPI0720525B1 (pt) 2020-03-03
ECSP099529A (es) 2009-08-28
CO6230984A2 (es) 2010-12-20
MA31151B1 (fr) 2010-02-01

Similar Documents

Publication Publication Date Title
TN2009000249A1 (en) Mapk/erk kinase inhibitors
WO2008115890A3 (en) Mapk/erk kinase inhibitors
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2008079787A3 (en) Glucokinase activators
MY150542A (en) Cmet inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2007104034A3 (en) Glucokinase activators
WO2008116107A3 (en) Piperazine derivatives as glucokinase activators
MY146989A (en) Kinase inhibitors
ATE479687T1 (de) Kinaseinhibitoren
WO2010008847A3 (en) Pi3k/m tor inhibitors
WO2008055236A3 (en) Mapk/erk kinase inhibitors
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
MY152749A (en) Pyrazole and fused pyrazole glucokinase activators
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TN2009000151A1 (en) Mapk/erk kinase inhibitors
WO2008054956A3 (en) Kinase inhibitors
WO2008045834A3 (en) Kinase inhibitors
WO2009129401A8 (en) Kinase inhibitors
TN2009000130A1 (en) Kinase inhibitors
WO2008089005A3 (en) Renin inhibitors

Legal Events

Date Code Title Description
FG Grant or registration